Rtw Investments Reduces $7M in Beta Bionics, Inc. ($BBNX)
RTW Investments trimmed its holdings in Beta Bionics by 500,000 shares, a 20% decrease.
Key Points
- RTW Investments reduced its Beta Bionics holdings by 500,000 shares, cutting its position by 20% to 2 million shares worth $29.06 million.
- Beta Bionics, trading at $14.53, has a market cap of about $647.5 million and a 52-week range of $8.80 to $32.71.
- Analysts maintain a 'buy' recommendation with a mean target price of $19.18, as multiple firms uphold positive outlooks.
RTW Investments has reduced its stake in Beta Bionics, Inc. (NasdaqGM: BBNX) by 500,000 shares, according to its latest Form 13F filing with the SEC. This cut represents a 20% decrease, leaving RTW with 2 million shares valued at approximately $29.06 million as of the reporting period.
What Changed in RTW Investments' Beta Bionics Position
RTW Investments trimmed its holdings in Beta Bionics from 2.5 million shares to 2 million. This 500,000-share reduction reflects a 20% decrease in its position. The value of the remaining shares is estimated at around $29.06 million.
Other Institutional Activity in Beta Bionics
Several other institutional investors also adjusted their positions in Beta Bionics. Eventide Asset Management, LLC increased its holdings by 950,760 shares, ending with 5,945,488 shares worth about $59.57 million. Soleus Capital Management, L.P. added 1,819,936 shares, bringing its total to 4,354,501 shares valued at approximately $43.63 million. Meanwhile, Morgan Stanley grew its stake by 768,181 shares, holding 4,227,634 shares valued at $42.36 million. On the other hand, Farallon Capital Management LLC reduced its holdings by 706,000 shares to a total of 3,607,920 shares, valued at about $36.15 million.
Beta Bionics Stock Snapshot
Shares of Beta Bionics (NasdaqGM: BBNX) traded around $14.53. The company has a market capitalization of approximately $647.5 million. Its 52-week low is $8.80, and its high is $32.71. The stock's 50-day moving average is $11.29, while the 200-day moving average is $18.57. Beta Bionics has a current ratio of 10.69 and a quick ratio of 9.39, with a debt-to-equity ratio of 2.55.
Recent Earnings
In its recent earnings report, Beta Bionics posted revenue of $110.24 million, reflecting a growth rate of 56.6%. However, the company is not yet profitable, with a net margin of -60.3% and a return on equity of -22.7%. The next earnings announcement is scheduled for July 21, 2026.
Analysts Set New Price Targets
On May 27, 2026, Goldman Sachs maintained its 'buy' rating on Beta Bionics with a price target of $17. B of A Securities kept a 'hold' rating with an $11 target on May 18, 2026. Earlier, on April 22, 2026, Leerink Partners and Stifel both maintained 'buy' ratings, with price targets of $24 and $20, respectively. The consensus among analysts is a 'buy', with a mean target price of $19.18 based on 11 opinions.
About Beta Bionics
Beta Bionics, Inc. is a healthcare company based in Irvine, California, specializing in medical devices. It focuses on developing bionic pancreas systems for insulin-dependent diabetes management. The company offers the iLet Bionic Pancreas and is working on other insulin delivery solutions. Founded in 2015, it collaborates with Xeris Pharmaceuticals and Abbott Diabetes Care to enhance its product offerings.
Bottom Line
RTW Investments' reduction in its Beta Bionics position highlights the dynamic nature of institutional investments. These 13F filings provide a snapshot of past holdings and might not reflect the current portfolio. Investors track such filings to gauge institutional sentiment and potential market movements.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.